A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A phase 3 trial of Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
Overview
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) is a phase 3 interventional study registered as NCT06943872 by BeOne Medicines, with 630 participants planned, started 2025-06-11 and due to reach its primary completion in 2029-09-30. Interventions recorded: Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Shares BeOne Medicines (formerly BeiGene), Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Shares Obinutuzumab, BeOne Medicines (formerly BeiGene), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Obinutuzumab, Rituximab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.